Gilead Sciences

Latest Stories

A pharmacist holds a vial of lenacapavir, an injectable HIV prevention drug, at the Desmond Tutu Health Foundation's Masiphumelele Research Site, in Cape Town, South Africa, Tuesday, July 23, 2024, which was one of the sites for Gilead's lenacapavir drug trial. (AP Photo/Nardus Engelbrecht) **FILE**

FDA approves the world’s only twice-a-year shot to prevent HIV

By Lauran Neergaard - Associated Press

In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. Given through an IV, the medication is designed to interfere with an enzyme that reproduces viral genetic material. (Gilead Sciences via AP)

Abusing Bayh-Dole Act for remdesivir would further jeopardize COVID-19 research

By David Winwood

Scientific Games; Nvidia rise; Marathon Oil, Hologic fall

Associated Press

FILE - This April 30, 2020, file photo shows Gilead Sciences headquarters in Foster City, Calif. Shares of Immunomedics more than doubled before the market open on Monday, Sept. 14 after Gilead Sciences said it'll buy the biotechnology company for $21 billion. (AP Photo/Ben Margot, File)

Gilead Sciences buying Immunomedics in $21 billion deal

Associated Press

A man walks in the rain past an electronic stock board showing Japan's Nikkei 225 index at a securities firm in Tokyo Friday, July 10, 2020. Asian stock markets followed Wall Street lower Friday on worries economic improvements might fade as coronavirus cases increase in the United States and some other countries. (AP Photo/Eugene Hoshiko)

Wall Street rallies as optimism returns to cap erratic week

By STAN CHOE and DAMIAN J. TROISE and ALEX VEIGA - Associated Press

President Donald Trump signs his name on a piece of paper during a roundtable with governors on the reopening of America's small businesses, in the State Dining Room of the White House, Thursday, June 18, 2020, in Washington. (AP Photo/Alex Brandon)

Health experts slam US deal for large supply of virus drug

By MARIA CHENG - Associated Press

In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. On Wednesday, the company says its experimental antiviral drug has proved effective against the new coronavirus in a major U.S. government study that put it to a strict test. (Gilead Sciences via AP) ** FILE **

HHS: U.S. has secured 500K courses of remdesivir, a COVID-19 treatment

By Tom Howell Jr. - The Washington Times

New Jersey Gov. Phil Murphy wears a mask during his daily coronavirus news conference at the War Memorial, Tuesday, May 19, 2020, in Trenton, N.J. (Chris Pedota/The Record via AP, Pool)

Governors roll back reopenings as coronavirus cases explode

By Tom Howell Jr. and Shen Wu Tan - The Washington Times

FILE - This is an April 30, 2020, file photo showing Gilead Sciences headquarters in Foster City, Calif. The maker of a drug shown to shorten recovery time for severely ill COVID-19 patients says it will charge $2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries. Gilead Sciences announced the price Monday, June 29 for remdesivir, and said the price would be $3,120 for patients with private insurance. It will sell for far less in poorer countries where generic drugmakers are being allowed to make it. (AP Photo/Ben Margot, File)

Gilead’s $2,340 price for coronavirus drug draws criticism

By MARILYNN MARCHIONE - Associated Press

In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. (Gilead Sciences via AP) ** FILE **

Gilead to start trials of inhaled remdesivir for COVID-19 in August

By Shen Wu Tan - The Washington Times

In this March 2020 file photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. Given through an IV, the medication is designed to interfere with an enzyme that reproduces viral genetic material. (Gilead Sciences via AP) ** FILE **

U.S. government anticipated to run out of remdesivir by end of June

By Shen Wu Tan - The Washington Times

FILE - This is an April 30, 2020, file photo showing Gilead Sciences headquarters in Foster City, Calif. A California biotech company says its experimental drug remdesivir improved symptoms when given for five days to moderately ill, hospitalized patients with COVID-19. Gilead Sciences gave few details on Monday, June 1, 2020, but said full results would soon be published in a medical journal. (AP Photo/Ben Margot, File)

Gilead says drug helped moderately ill coronavirus patients

By MARILYNN MARCHIONE - Associated Press

President Donald Trump speaks during a meeting with restaurant industry executives about the coronavirus response, in the State Dining Room of the White House, Monday, May 18, 2020, in Washington. (AP Photo/Evan Vucci)

Donald Trump taking hydroxychloroquine to stave off coronavirus

By Tom Howell Jr. - The Washington Times

In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. On Wednesday, the company says its experimental antiviral drug has proved effective against the new coronavirus in a major U.S. government study that put it to a strict test. (Gilead Sciences via AP) ** FILE **

FDA authorizes emergency use of remdesivir for COVID-19 patients, Trump says

By Tom Howell Jr. - The Washington Times

FILE - In this March 2020 photo provided by Gilead Sciences, rubber stoppers are placed onto filled vials of the investigational drug remdesivir at a Gilead manufacturing site in the United States. Given through an IV, the medication is designed to interfere with an enzyme that reproduces viral genetic material. (Gilead Sciences via AP)

A coronavirus drug seems to work. What’s next?

By MARILYNN MARCHIONE - Associated Press

In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. On Wednesday, the company says its experimental antiviral drug has proved effective against the new coronavirus in a major U.S. government study that put it to a strict test. (Gilead Sciences via AP) ** FILE **

Gilead Sciences reports promising early results in COVID-19 trial using remdesivir

By Tom Howell Jr. - The Washington Times

In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. (Gilead Sciences via AP) ** FILE **

A 1st: US study finds Gilead drug works against coronavirus

By MARILYNN MARCHIONE - Associated Press

In this Monday, March 2, 2020 file photo, Gilead Sciences CEO Daniel O'Day speaks at a meeting with President Donald Trump, members of the Coronavirus Task Force, and pharmaceutical executives in the Cabinet Room of the White House in Washington. Gilead, the pharmaceutical giant that makes remdesivir, a promising coronavirus drug, has registered it as a rare disease treatment with U.S. regulators on Monday, March 23, 2020, a status that can potentially be worth millions in tax breaks and competition-free sales. (AP Photo/Andrew Harnik) **FILE**

Drugmaker backpedals on specialty status for COVID-19 drug

By Matthew Perrone - Associated Press

Gilead Sciences buying Forty Seven for $4.9 billion

Associated Press

Dr. Andre Kalil, of the University of Nebraska Medical Center, speaks in Omaha, Neb., Tuesday, Feb. 25, 2020. Dr. Kalil, Kalil, who will oversee a clinical trial of the coronavirus at the medical center, said the study developed quickly in response to the virus outbreak that is centered in China. Patients who are hospitalized with the COVID-19, the disease caused by the virus, will be eligible to join the trial if they have at least moderate symptoms. (AP Photo/Nati Harnik)

Study begins in US to test possible coronavirus treatment

By JOSH FUNK - Associated Press